Ubs Asset Management Americas Inc Biocryst Pharmaceuticals Inc Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 401,111 shares of BCRX stock, worth $3.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
401,111
Previous 389,530
2.97%
Holding current value
$3.2 Million
Previous $2.96 Million
1.89%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
167MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.9MShares$175 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$159 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$94.7 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$72.5 Million4.33% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$65 Million1.52% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.48B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...